EE200100359A - Kristalliline bis[(E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüülsulfonüül)amino]pürimidiin-5-üül](3R,5S)-3,5-dihüdroksühept-6-enool happe]kaltsiumisool - Google Patents

Kristalliline bis[(E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüülsulfonüül)amino]pürimidiin-5-üül](3R,5S)-3,5-dihüdroksühept-6-enool happe]kaltsiumisool

Info

Publication number
EE200100359A
EE200100359A EEP200100359A EEP200100359A EE200100359A EE 200100359 A EE200100359 A EE 200100359A EE P200100359 A EEP200100359 A EE P200100359A EE P200100359 A EEP200100359 A EE P200100359A EE 200100359 A EE200100359 A EE 200100359A
Authority
EE
Estonia
Prior art keywords
dihydroxyhept
methylsulfonyl
pyrimidin
fluorophenyl
isopropyl
Prior art date
Application number
EEP200100359A
Other languages
English (en)
Inventor
Philip Taylor Nigel
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200100359A publication Critical patent/EE200100359A/et
Publication of EE05033B1 publication Critical patent/EE05033B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200100359A 1999-01-09 1999-12-23 Kristalliline bis[(E)-7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5- l](3R,5S)-3,5-dihdrokshept-6-enool happe]kaltsiumisool EE05033B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9900339.4A GB9900339D0 (en) 1999-01-09 1999-01-09 Chemical compounds
PCT/GB1999/004439 WO2000042024A1 (en) 1999-01-09 1999-12-23 Crystalline bis[(e)-7- [ 4-(4- fluorophenyl)- 6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] (3r,5s)-3, 5-dihydroxyhept -6-enoic acid]calcium salt

Publications (2)

Publication Number Publication Date
EE200100359A true EE200100359A (et) 2002-12-16
EE05033B1 EE05033B1 (et) 2008-06-16

Family

ID=10845719

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100359A EE05033B1 (et) 1999-01-09 1999-12-23 Kristalliline bis[(E)-7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5- l](3R,5S)-3,5-dihdrokshept-6-enool happe]kaltsiumisool

Country Status (32)

Country Link
US (2) US6589959B1 (et)
EP (1) EP1144389B1 (et)
JP (2) JP4996786B2 (et)
KR (1) KR100645858B1 (et)
CN (1) CN1213033C (et)
AT (1) ATE282027T1 (et)
AU (1) AU762909B2 (et)
BR (1) BR9916786A (et)
CA (1) CA2356212C (et)
CZ (1) CZ299843B6 (et)
DE (1) DE69921855T2 (et)
DK (1) DK1144389T3 (et)
EE (1) EE05033B1 (et)
ES (1) ES2232194T3 (et)
GB (1) GB9900339D0 (et)
HK (1) HK1040989B (et)
HU (1) HU228116B1 (et)
ID (1) ID29432A (et)
IL (1) IL143977A0 (et)
IN (2) IN213326B (et)
IS (1) IS2410B (et)
MX (1) MX223771B (et)
NO (1) NO320189B1 (et)
NZ (1) NZ512560A (et)
PL (1) PL201800B1 (et)
PT (1) PT1144389E (et)
RU (1) RU2236404C2 (et)
SI (1) SI1144389T1 (et)
SK (1) SK285807B6 (et)
TR (1) TR200101894T2 (et)
WO (1) WO2000042024A1 (et)
ZA (1) ZA200105187B (et)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
DE10135493A1 (de) * 2001-07-20 2003-01-30 Jobst Krauskopf Pharmazeutische Zusammensetzung zur Behandlung von Hypercholesterinämie
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
CA2523233C (en) * 2003-04-25 2012-03-20 Nippon Chemiphar Co., Ltd. Salt of (2s,3s)-3-[[(1s)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
TW200526596A (en) * 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
CZ200486A3 (cs) * 2004-01-16 2005-08-17 Zentiva, A.S. Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny
EP1737828A1 (en) * 2004-01-19 2007-01-03 Ranbaxy Laboratories Limited Amorphous magnesium salts of rosuvastatin
EP1709008A1 (en) * 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
EP1797046A2 (en) * 2004-09-27 2007-06-20 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
EP1844021A1 (en) * 2005-01-31 2007-10-17 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
CA2612587C (en) 2005-06-24 2013-02-19 Lek Pharmaceuticals D.D. Process for preparing amorphous rosuvastatin calcium free of impurities
CZ299215B6 (cs) * 2005-06-29 2008-05-21 Zentiva, A. S. Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
KR20070062996A (ko) * 2005-08-16 2007-06-18 테바 파마슈티컬 인더스트리즈 리미티드 결정성 로수바스타틴 중간체
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
EP2066644A2 (en) * 2006-08-04 2009-06-10 Glenmark Pharmaceuticals Limited Salts of rosuvastatin and processes for their preparation
KR20080060284A (ko) * 2006-09-18 2008-07-01 테바 파마슈티컬 인더스트리즈 리미티드 결정질 로수바스타틴 칼슘
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
KR20090127904A (ko) * 2007-04-09 2009-12-14 싸이도우스 엘엘씨. 스타틴과 항비만제의 복합물
WO2009143776A1 (zh) 2008-05-27 2009-12-03 常州制药厂有限公司 瑞舒伐他汀钙盐的制备方法及其中间体
EP2336116A1 (en) * 2009-12-16 2011-06-22 LEK Pharmaceuticals d.d. Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
WO2011074016A1 (en) 2009-12-17 2011-06-23 Matrix Laboratories Ltd Novel polymorphic forms of rosuvastatin calcium and process for preparation of the same
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP2643305A1 (en) 2010-11-22 2013-10-02 Basf Se Multicomponent system of rosuvastatin calcium salt and sorbitol
CA2832343A1 (en) 2011-04-18 2012-10-26 Basf Se Multicomponent crystalline system of rosuvastatin calcium salt and vanillin
WO2014050874A1 (ja) * 2012-09-27 2014-04-03 東和薬品株式会社 ロスバスタチンカルシウムの新規結晶形態およびその製造方法
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
CN103755643A (zh) * 2013-12-31 2014-04-30 连云港金康医药科技有限公司 瑞苏伐他汀钙盐i晶型
CN105153040B (zh) * 2015-10-15 2018-04-13 江苏师范大学 瑞舒伐他汀钙新晶型及其制备方法
US10626093B2 (en) 2016-04-18 2020-04-21 Morepen Loboratories Limited Polymorphic form of crystalline rosuvastatin calcium and novel processes for crystalline as well as amorphous rosuvastatin calcium
CN105837516B (zh) * 2016-05-16 2018-07-10 山东新时代药业有限公司 一种瑞舒伐他汀钙晶型及其制备方法
TW202302090A (zh) * 2021-04-30 2023-01-16 大陸商江蘇恒瑞醫藥股份有限公司 血小板生成素受體激動劑的給藥方案

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
PL348775A1 (en) 2002-06-17
CN1213033C (zh) 2005-08-03
GB9900339D0 (en) 1999-02-24
RU2236404C2 (ru) 2004-09-20
US20040009997A1 (en) 2004-01-15
CN1333756A (zh) 2002-01-30
IS2410B (is) 2008-10-15
EP1144389A1 (en) 2001-10-17
SI1144389T1 (en) 2005-06-30
US6589959B1 (en) 2003-07-08
IL143977A0 (en) 2002-04-21
CA2356212C (en) 2009-08-04
SK285807B6 (sk) 2007-08-02
DE69921855T2 (de) 2005-11-24
ES2232194T3 (es) 2005-05-16
EP1144389B1 (en) 2004-11-10
IN213326B (et) 2008-01-25
HK1040989A1 (en) 2002-06-28
CZ299843B6 (cs) 2008-12-10
IS5977A (is) 2001-06-22
CA2356212A1 (en) 2000-07-20
AU1882600A (en) 2000-08-01
CZ20012460A3 (cs) 2001-10-17
BR9916786A (pt) 2001-10-16
NO20013368D0 (no) 2001-07-06
AU762909B2 (en) 2003-07-10
JP4996786B2 (ja) 2012-08-08
HK1040989B (zh) 2005-05-06
DE69921855D1 (en) 2004-12-16
ID29432A (id) 2001-08-30
WO2000042024A1 (en) 2000-07-20
SK9632001A3 (en) 2001-12-03
NO320189B1 (no) 2005-11-07
PT1144389E (pt) 2005-02-28
KR100645858B1 (ko) 2006-11-14
HUP0104828A3 (en) 2002-10-28
JP2010090128A (ja) 2010-04-22
IN2001MU00758A (et) 2005-06-17
HU228116B1 (en) 2012-11-28
NZ512560A (en) 2003-08-29
MXPA01006953A (es) 2001-10-01
EE05033B1 (et) 2008-06-16
HUP0104828A2 (hu) 2002-07-29
ZA200105187B (en) 2002-09-23
TR200101894T2 (tr) 2001-12-21
KR20010101390A (ko) 2001-11-14
MX223771B (en) 2004-10-27
NO20013368L (no) 2001-09-05
ATE282027T1 (de) 2004-11-15
IN2003MU00223A (et) 2005-03-04
JP2002539078A (ja) 2002-11-19
DK1144389T3 (da) 2005-02-14
PL201800B1 (pl) 2009-05-29

Similar Documents

Publication Publication Date Title
EE200100359A (et) Kristalliline bis[(E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüülsulfonüül)amino]pürimidiin-5-üül](3R,5S)-3,5-dihüdroksühept-6-enool happe]kaltsiumisool
DE60132178D1 (de) CRISTALLINSALZE VON 7-i4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-iMETHYL(METHYLSULFONYL)AMINO PYRIMIDIN-5-YL -(3R,5S)-3,5-DIHYDROXYHEPT-6-ENSÄURE
AP1879A (en) Pharmaceutical compositions comprising a HMG CoA reductase inhibitor.
MXPA05013128A (es) Produccion mejorada de sal calcica de rosuvastatina.
MY146002A (en) Process for the manufacture of the calcium salt of rosuvatatin (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl) amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20161223